MedPath

Evaluation of tau deposition using Florzolotau in young, healthy volunteers

Not Applicable
Conditions
Not Applicable
Registration Number
KCT0008809
Lead Sponsor
Gachon University Gil Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Healthy subjects aged 20 or older but younger than 40 years old.

Exclusion Criteria

-Pregnant women (Excluded if there is even the slightest suspicion of pregnancy based on questionnaire responses, including the last menstrual date).
-Currently breastfeeding women.
-Patients with such poor overall health that it is difficult to perform the examination.
-Individuals with conditions such as claustrophobia or other seizures.
-Patients with clear diagnoses of other causes of dementia or major neurological conditions, including traumatic brain injury, Parkinson's disease, Huntington's disease, motor neuron diseases, multiple sclerosis, etc.
-Patients diagnosed with psychiatric disorders such as schizophrenia.
-Patients with brain tumors, hydrocephalus, encephalitis, metabolic encephalopathies.
-Women who are pregnant or using intrauterine contraceptive devices.
-Individuals with cardiac pacemakers or metallic substances implanted inside the body (However, exclusion does not apply if the implanted/transplanted material is titanium or a titanium alloy or if a specialist has confirmed that there are no issues with a 3T MRI scan).
-Patients with metallic substances in the brain area, such as brain vascular clips, orthodontic devices, that can cause distortion of the MRI image.
-Individuals who have been exposed to radiation exceeding an effective dose of 50msV (5rem) in the past year.
-Individuals who have undergone PET scans, coronary angiograms, abdomen-pelvic CT scans, or similar procedures more than twice in the past year.
-Individuals working in jobs with significant radiation exposure.
-Other individuals who are deemed inappropriate for participation by the clinical investigator.

Study & Design

Study Type
Observational Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Formation of Florzolotau SUVR average maps for healthy subjects
Secondary Outcome Measures
NameTimeMethod
Calculation of SUVR values in 6 regions associated with Braak stages
© Copyright 2025. All Rights Reserved by MedPath